In January, medication abortion returned to the national spotlight. On January 14, 2026, the Senate Health, Education, Labor, and Pensions Committee held a hearing titled “Protecting Women: Exposing the Dangers of Chemical Abortion Drugs.” The focus was mifepristone, one of the two medications used in medication abortion. At first glance, a Senate hearing in Washington, D.C., may feel far removed from Montana. But when federal lawmakers revisit how a medication is regulated,

A recent House vote to redirect TANF safety net dollars to unregulated pregnancy centers has real consequences. And it's worth understanding exactly what changed and why it matters.